Clinical Trial

The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This randomized phase II trial is to explore the clinical efficacy, safety and feasibility of neoadjuvant immunotherapy plus radiotherapy compared with neoadjuvant immunotherapy plus chemotherapy in operable stage II-IIIA (N+) non small cell lung cancer (NSCLC) and the optimal radiotherapy pattern.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-04-02; most recent amendment 2026-03-09.
Trial Details
NCT Number NCT05798845
Lead Sponsor Shanghai Chest Hospital
Collaborators: Shanghai Junshi Bioscience Co., Ltd.
Conditions NSCLC
Enrollment 124 participants
Start Date 2025-02-20
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-11